Source: Annual Congress 2006 - Drug-induced lung injury – new aspects



Rating:

Share or cite this content

Citations should be made in the following way:
P. Rivera (Chapel Hill, United States of America). Lung disease induced by newer therapies for lung cancer: an update. Annual Congress 2006 - Drug-induced lung injury – new aspects

Member's Comments

No comment yet.

Related content which might interest you: Cardiovascular effects of innovative therapies in lung cancer Source: Eur Respir Monogr 2020; 88: 154-166 Year: 2020 Surfactant protein-D level as a predictor of prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer Source: International Congress 2016 – Orphan diseases I Year: 2016 Innovative systemic lung cancer therapies Source: International Congress 2018 – PG11 Modern approaches in lung cancer diagnostics and therapy Year: 2018 Common therapeutic approaches in IPF and lung cancer Source: Research Seminar 2015 Year: 2015 Impact of COPD on prognosis of lung cancer: the prespective of immunotherapy treatment Source: Virtual Congress 2021 – Therapy of lung cancer Year: 2021 Innovative local therapies in lung cancer Source: International Congress 2018 – PG11 Modern approaches in lung cancer diagnostics and therapy Year: 2018 Lung cancer and lung tuberculosis: Our results of treatment in the combined lung disease Source: International Congress 2016 – Surgical strategy for complex diseases Year: 2016 Biomarkers in early-detection of lung cancer: current concepts Source: Virtual Congress 2021 – Biomarkers in early-detection of lung cancer: current concepts Year: 2021 Incidence of interstitial lung disease (ILD) and risk factors for developing ILD: A final analysis of a large-scale erlotinib Japanese surveillance study in non-small-cell lung cancer (NSCLC) Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 Impact of interstitial lung disease and simultaneous lung cancer on therapeutic possibilities and survival Source: International Congress 2019 – Comorbidities of idiopathic pulmonary fibrosis Year: 2019 Lung cancer: does age affect treatment strategy? Source: Eur Respir Mon; 2009: 43:306–326 Year: 2009 New and emerging targeted treatments in advanced lung cancer Source: International Congress 2016 – Lung cancer: latest developments in screening and patient management Year: 2016 Novel approaches in metastasised non-small cell lung cancer with a special focus on modern systemic therapies Source: International Congress 2019 – State of the art session: Thoracic oncology Year: 2019 Immunotherapy for nonsmall cell lung cancer: a new therapeutic algorithm Source: Eur Respir J, 55 (2) 1901907; 10.1183/13993003.01907-2019 Year: 2020 New and anticipated therapeutic developments in management of non-small-cell lung cancer Source: Annual Congress 2013 –ERS/The Lancet/The Lancet Respiratory Medicine joint Lunchtime session on lung cancer Year: 2013 Advances in target therapy for lung cancer Source: International Congress 2014 – Ceremony for the ERS Romain Pauwels Research Award 2014 - Clinical Year in Review I Year: 2014 Advances in target therapy in lung cancer Source: Eur Respir Rev 2015; 24: 23-29 Year: 2015 Interstitial lung disease associated by gemcitabine chemotherapy in non-small lung cancer patients: Analysis based on the data in practical use with confirmed denominator Source: Annual Congress 2011 - Clinical perspectives in several interstitial diseases Year: 2011